国立がん研究センター中央病院では、もっと腫瘍内科の魅力をお伝えするため、
「若手医師のための腫瘍内科ステップアップセミナー」を開催します!!
STEP: Seminar for Training in mEdical oncology and Professional skills development
We are participating in the Mansfield-PhRMA Research Scholars Program.
We will travel from Washington DC to Philadelphia and Boston over a two-week period.
科研費(若手)採択いただきました。社会的な研究でもインパクトを残したい!
I have been selected for Grant-in-Aid for Scientific Research (Young Scientists) . I would like to leave an impact in social research!
国立がん研究センター中央病院腫瘍内科主催の「若手医師のための腫瘍内科ステップアップセミナー」についてのお知らせです!
国立がん研究センター中央病院腫瘍内科では、さらに腫瘍内科の魅力をお伝えするためのセミナーを開催します!!
STEP: Seminar for Training in mEdical oncology and
国立がん研究センター中央病院では、もっと腫瘍内科の魅力をお伝えするため、
「若手医師のための腫瘍内科ステップアップセミナー」を開催します!!
STEP: Seminar for Training in mEdical oncology and Professional skills development
@CarmenCriscit
approaching several controversies in the real world oncology in BRCA/HR+ adjuvant scenario
▪️How to choose between CDKi and PARPi?
▪️ Are CDKi less effective in BRCAmut?
▪️ Can we combine at least sequentially CDKi and PARPi?
#ESMOBreast24
#ESMOAmbassadors
#ASCO24
PEARLY
Stg 2-3
#TNBC
#breastcancer
(N=868) of AC-tax +/- q3w carbo
Carbo ⬆️ EFS at 5y (HR 0.67, p=.012, abs ⬆️ of ~7%) at cost of 20% abs ⬆️ in gr 3+ tox. Number needed to treat of ~14.
OS HR 0.65, 3.7% abs ⬆️, p=.057
TL;DR: sorry
#bcsm
, I think we do need the carbo
The results of our international collaborative study have been published in JAMA!
The study addresses the clinical question, "In patients with early-stage triple-negative breast cancer (TNBC), does a higher amount of tumor-infiltrating lymphocytes (TILs) in breast cancer tissue
Just published!
The results of the Phase 2 study (BELIEVE study; NCCH1901) of dabrafenib-trametinib combination therapy across cancer types in Japan have just been published in eClinicalMedicine part of the Lancet discovery science.
#presicionmedicine
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations
2488例のうち、BRCA1がほとんどだが、乳がん死亡リスクを、8割下げるHR0.2はすごい結果
Of the 2488 cases, most were BRCA1, but the HR of 0.2, which reduces the risk of breast cancer death
やはりcapivasertibの投与可否を決めるためにはPIK3CA/AKT1/PTEN-alterations をコンパニオン検査で決めねばなりません。F1CDxのコンパニオン検査が乳癌でも必要ですね。
FDA approves capivasertib with fulvestrant for breast cancer | FDA
Negative results of Impassion132 of the addition of atezolizumab to chemotherapy in early relapse TNBC presented by
@RebeccaDSing
. So much still needed for this population.
#ESMOBreast24
#ESMOAmbassadors
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
#ASCO24
NRG-LU002: maintenance systemic therapy vs local consolidative therapy plus maintenance therapy in oligometastatic NSCLC
90% having received IO-based therapy
Adding LCT does not improve survival🚫
It increases side effects⚠️
Presented by Dr. Puneeth Iyengar
A paper describing the progress of the Japanese version of the NCI-MATCH trial has also been published.
Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE Trial - Ando - Cancer Science - Wiley Online Library
PostMonarch: Abemaciclib after progression on CDK4/6 inhib shows 27% reduction in PFS. All subgroups, all biomarkers seem to benefit.
Valuable in the current landscape; sets the stage for EMBER-3 w/oral SERD + CDK4/6 and allows maximal ET in MBC
#ASCO24
@OncoAlert
(COI/author)
@matteolambe
Today, Dr. Matteo Lambertini, visiting Japan for the second time, gave a great lecture on endocrine therapy for breast cancer.
I asked him about the relationship between BRCA mutations and Rb1 LOH, as well as the efficacy of CDK4/6 inhibitors, and I also asked him
@YukinoriOzaki
@PTarantinoMD
@ErikaHamilton9
@hoperugo
@kazuki_nozawa
Dr. Ozaki's words from yesterday.
There are many young oncologists gathered here today, but there are young, ambitious oncologists in Japan! Your words really stuck with me. Let's work together to develop clinical trials that will change the future of cancer treatment!
Accumulative publications showing that immunotherapy is more potent when given early in the day. Time to change our practice and give our IOs in the morning? At least until evidence of a circadian biology supporting the hypothesis & availability of data from phase III trials?
Key real world evidence data set from Italy 🇮🇹 comparing 3 CDK4/6 inhibitors gives some clues to benefits of Abemaciclib and Ribociclib.
#ASCO24
#bcsm
@OncoAlert
#ASCO24
DESTINY-Breast06: T-DXd vs TPC in pts with HR+/ HER2-low or HER2-ultralow
PFS
Low➡️13.2 vs 8.1 mo
Ultralow➡️13.2 vs 8.3 mo
ORR
Low➡️56.5 vs 32.2%
Ultralow➡️61.8 vs 26.3%
ILD➡️11.3% (0.7% Gr3/4, 0.7% Gr5) vs 0.2% (Gr2)
❗️Attention should be paid to ILD
💥Even if
The
#STATICE
phase 2 trial of T-DXd for HER2-expressing uterine carcinosarcoma is out on JCO. Of 32 patients receiving T-DXd, both HER2-high & HER2-low pts achieved ORR>50%. Impressive activity for a rare, but very aggressive disease. High ILD rate (27%).
EMERALD trial
For more than a decade, there have been no options for first-line treatment of HER2-positive MBC, and the CLEOPATRA regimen has been the best. This new non-inferiority option, eribulin based regimen will be presented.
#ASCO24
phase 1/2 trial of H3B-6545, a novel selective ER covalent antagonist (SERCA) in mHR+BC shows low G3 AEs
and good antitumor efficacy to support advancing in further development
@ErikaHamilton9
#ASCO24
#SABCS23
DESTINY Breast08
T-DXd +ANA or FUL
after ET± targeted therapy
No prior CTx
✅ORR ANA 71.4%, FUL 40.0%
✅PFS ANA 13.4m, FUL NE
Study to suggest whether T-DXd is effective in restoring endocrine therapy sensitivity.
Would like to see long term results.
A-BRAVE phase 3: among pts with TNBC and (mostly) RD after NACT, adjuvant avelumab for 1 year did not sign improve DFS (68.3% vs 63.2%, p=0.1) but did improve DDFS and OS (84.8% vs 76.3%, p=0.02), with low rate of AE. Impressive academic effort with extremely interesting results.
Can we give abemaciclib post progression on cdk inhibitors? Post MONARCH trial . It shows PFS benifit. 6 months PFS benifit 50 % vs 37 %. HR of 0.73. Os immature. Looks interesting.
@asco
#asco24
@OncoAlert
@Larvol
My poster of LIBRA study.
The intervention based on daily ePROs reduced the frequency of diarrhea and improved QOL in patients with advanced breast cancer treated with abemaciclib.
Please come to Board
#305
.
#ASCO24
#BCSM
#LIBRA
#HBM
#ePRO
Looking at the TROPION-01 update analysis, were you curious about the concordance of TROP2 expression between primary and metastatic sites?
Our poster has the answer.
VISIT PO03-15-12
#SABCS23
脳転移、髄膜転移の日本からのレトロ
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) | npj Breast Cancer
#SABCS23
Dr. Shimomura appeared in the SABCS Rapid fire session.
The trial was negative, although it tested the non-inferiority of T-DM1 to HPD as 1st line treatment for elderly HER2 positive MBC.
JCOG1607
Now we are pleased to announce that dabrafenib-trametinib combination therapy is now covered by insurance for patients with BRAF V600E mutated solid tumors, with the exception of colorectal cancer. New precision medicine is now available in Japan.
A commentary paper on the Japanese version of the NCI-MATCH study has been published.
What is NCCH1901 BELIEVE trial?
How is precision medicine in JPAPN?
@dr_yakupergun
I think it is important to note that the safety of oral capecitabine (at a dose of 1250 mg/m2, twice per day, on days 1 to 14) in combination with pembrolizumab was not clear. The lack of safety assurance of capecitabine in combination with pembro may have been a major barrier.